TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic... TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic conditions. Its lead product, BRIUMVI (ublituximab‑xiiy), is an anti‑CD20 monoclonal antibody indicated for relapsing forms of multiple sclerosis, addressing a key segment of the neurology market where efficacy, infusion profile, and safety are central considerations. The company’s revenue base has increasingly centered on BRIUMVI’s U.S. uptake, reflecting its strategic transition from development to commercial execution and providing a recurring product revenue foundation. TG Therapeutics operates within the broader pharmaceuticals sector and is tracked on international venues including the Italian market under a global equity listing framework, with third‑party services providing pricing, market data, and coverage for investors and analysts. Its positioning highlights the role of targeted B‑cell therapies in autoimmune disease management, and its activities contribute to innovation pipelines and competitive dynamics among neurologic and immunology therapeutics developers.
Pending data availability
Climate Targets Data missing for TG Therapeutics
We haven’t collected Climate Targets data for TG Therapeutics yet, or the company
hasn’t made it publicly available.